Immune Profiling for Cancer Immunotherapy Response

Part of paid clinical trials in Lebanon, New Hampshire.

Sponsor
Dartmouth-Hitchcock Medical Center
Study ID
NCT06116032
Status
Recruiting
Apply to this trial

Conditions

  • Blood Cancer
  • Cancer
  • Hematologic Malignancy
  • Tumor, Solid

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Methylation Cytometry — DIAGNOSTIC_TEST
    Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.

Study Details

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Key Dates

Start date
Oct 3, 2022
Status verified
Dec 2025
Primary completion
Jan 1, 2027
Completion
Jan 1, 2029

Study Design

Enrollment
1,500 participants (estimated)

Arms

  • Arm: Standard of Care Checkpoint
    Patients receiving standard of care FDA approved immunotherapy
  • Arm: Bone Marrow Transplant
    Patients undergoing transplant for hematologic malignancy
  • Arm: CAR T
    Patients undergoing CAR T therapy

Primary Outcome Measure

Response to therapy [ Time Frame: 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dartmouth-Hitchcock Medical CenterLebanonNew Hampshire03756
Hannah G Stolrow, BA
[email protected]
7205174950
Brock C Christensen, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Lebanon, NH

By research site
Dartmouth-Hitchcock Medical Center· Lebanon, NH

Related Studies